市場調査レポート

商品コード

1803084

肝線維症治療市場の2032年までの予測：治療タイプ、病態、流通チャネル、地域別の世界分析

Liver Fibrosis Treatment Market Forecasts to 2032 - Global Analysis By Treatment Type, Condition, Distribution Channel and By Geography

出版日: 2025年09月07日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 615,735円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 778,942円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 942,149円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,112,775円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.37円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、肝線維症治療の世界市場は2025年に207億1,000万米ドルを占め、予測期間中にCAGR 13.05％で成長し、2032年には488億7,000万米ドルに達すると予測されています。

肝線維症の治療は、進行中の肝障害や炎症に起因する瘢痕組織形成の減少または回復を目標とします。治療には、ウイルス性肝炎、飲酒、非アルコール性脂肪肝などの根本的な原因を管理し、薬物療法、生活習慣の改善、支持療法を併用して、さらなる害を最小限に抑えることが含まれます。適時治療を行うことで、肝機能を維持し、病気の進行を遅らせ、肝硬変を発症するリスクを下げることができ、最終的には全体的な健康と予後を改善することができます。

米国アルコール乱用・アルコール依存症研究所（National Institute on Alcohol Abuse and Alcoholism 2023）によると、2022年には米国で約2,950万人がアルコール依存症に罹患しており、これは12歳以上の10.5％に相当します。

老年人口の増加

世界的な高齢者の増加は、肝線維症治療に対する需要を大幅に押し上げています。高齢者は、加齢に伴う免疫力の低下や代謝ストレス要因に長期間さらされることにより、肝障害を起こしやすくなります。肥満、糖尿病、心臓病などの疾患はしばしば併存し、肝臓の悪化を加速させます。長寿化が進むにつれて、ヘルスケアプロバイダーは高齢患者に合わせた治療法の必要性を感じています。この動向は、高齢者により安全で効果的な抗線維化薬の選択肢に焦点を当てた医薬品の技術革新を促しています。最終的には、高齢化層が治療市場を拡大し、臨床開発の方向性に影響を与えています。

承認された抗線維化薬の入手が限られている

利用可能な治療薬のほとんどは、線維化障害を回復させるのではなく、ウイルス性肝炎や脂肪性肝疾患のような根本的な原因の管理に集中しています。規制の複雑さと開発期間の延長が、新しい治療法の導入を遅らせています。有望な化合物の多くはまだ初期の研究段階にあり、臨床医が目標とする解決策はほとんどないです。この不足は患者の治療に影響を与え、特に高負担地域における市場拡大を制限しています。より多くの抗線維化薬が承認されるまでは、治療の選択肢は制限されたままだと思われます。

遠隔医療とデジタルヘルスプラットフォームの拡大

デジタルヘルスと遠隔医療の台頭は、肝線維症の管理に新たな道を開いています。バーチャル診察により、患者は肝臓専門医にアクセスし、特に遠隔地や十分な医療を受けていない地域でタイムリーな治療を受けることができます。ウェアラブルやモバイルアプリは肝機能指標をモニターし、服薬アドヒアランスをサポートすることができます。これらの技術はまた、オーダーメイドの治療計画を可能にし、患者教育を向上させ、より良い健康アウトカムを育みます。デジタルヘルスケアが主流になるにつれ、肝線維症ケアはより積極的で利用しやすくなっています。このシフトは、革新的な治療法の広範な採用を促進し、疾患管理を強化すると予想されます。

代替療法との競合

代替療法は、従来の肝線維症治療の優位性にますます課題しています。生活習慣の改善、食事介入、代謝コントロールのような予防戦略は、第一選択のアプローチとして支持を集めています。再生技術や細胞を用いた治療もまた、従来の薬物治療をバイパスする新しい解決策を提供しています。このように選択肢の幅が広がることで、薬理学的介入への依存度が低下する可能性があります。さらに、非侵襲的な方法が有効であることが証明されれば、臨床医は新薬の採用に慎重になるかもしれないです。

COVID-19の影響：

COVID-19の流行は肝線維症治療市場に顕著な影響を及ぼし、診断、定期検診、必要のない医療処置に遅れが生じました。治療スケジュールはしばしば延期され、その結果、患者によっては病気が進行する可能性がありました。サプライチェーンの混乱は医薬品や診断ツールの入手を妨げました。COVID-19が肝機能に影響を及ぼす可能性があることから、早期発見と効果的な治療の重要性が強調されました。

ペルオキシソーム増殖剤セグメントは予測期間中最大となる見込み

ペルオキシソーム増殖剤セグメントは、ハイスループット・スクリーニングや分子モデリングなどの創薬技術の進歩により、予測期間中最大の市場シェアを占めると予想されます。デュアルPPARアゴニストや汎PPARアゴニストの開発といった新たな動向は、より広範な治療効果をもたらします。主な発展には、有望な臨床試験結果や、イノベーションを加速するための製薬企業間の戦略的提携が含まれます。非アルコール性脂肪性肝炎（NASH）および関連する代謝障害の有病率の増加は、PPARベースの治療を肝線維症管理における重要なセグメントとして位置づけ、需要をさらに促進しています。

病院薬局セグメントは予測期間中最も高いCAGRが見込まれる

予測期間中、病院薬局部門が最も高い成長率を示すと予測されます。これは、自動薬剤分配や電子処方システムといった調剤技術の進歩が、効率性と正確性を向上させているためです。新たな動向としては、遠隔調剤サービスの統合や肝疾患患者に対する個別化医療アプローチが挙げられます。臨床試験や早期医薬品入手プログラムのための製薬会社との病院提携などの開発。肝臓関連疾患による入院率の上昇や、先進的な治療法の利用可能性の増加は、治療提供における病院薬局の役割をさらに強化しています。

最大のシェアを占める地域：

予測期間中、肝炎、NASH、アルコール誘発性肝障害に関連する症例の増加により、アジア太平洋地域が最大の市場シェアを占めると予想されます。非侵襲的画像診断とRNA治療薬の技術革新により、早期診断と的を絞った治療が強化されています。同市場では、デジタルヘルスの導入と個別化治療アプローチが伸びています。注目すべき進展としては、インド、日本、中国における新薬候補と試験活動の拡大が挙げられます。人口の高齢化、健康意識の高まり、政府投資の増加が、技術の進歩と地域市場の成長に拍車をかけています。

CAGRが最も高い地域：

予測期間中、北米地域は、NASH、NAFLD、肝炎の有病率の増加、強固な医療制度と研究資金に支えられていることから、最も高いCAGRを示すと予測されます。AI主導の診断、非侵襲的技術、RNA治療薬におけるブレークスルーは、精度と早期介入を向上させています。遠隔医療やオーダーメイド治療といった動向も牽引役となっています。最近の進展としては、PPAR標的の新薬、多剤併用療法、臨床試験ネットワークの拡大などがあります。健康リテラシーの向上、有利な規制、活発な医薬品パイプラインが、この地域全体の持続的な市場拡大を後押ししています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第9章主な発展

契約、パートナーシップ、コラボレーション、ジョイントベンチャー
買収と合併
新製品発売
事業拡大
その他の主要戦略

第10章企業プロファイリング

Abbott Laboratories
Bristol-Myers Squibb Company
Akero Therapeutics
Hepion Pharmaceuticals
Alentis Therapeutics
Inventiva Pharma
Alnylam Pharmaceuticals
Johnson & Johnson
Astellas Pharma Inc.
Novartis AG
Boehringer Ingelheim
Merck & Co., Inc.
Pfizer Inc.
Sanofi AG
Vertex Pharmaceuticals Incorporated
Galectin Therapeutics, Inc.
Takeda Pharmaceutical Company
Gilead Sciences, Inc.
Madrigal Pharmaceuticals, Inc.
GlaxoSmithKline PLC

図表

List of Tables

Table 1 Global Liver Fibrosis Treatment Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 3 Global Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
Table 4 Global Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
Table 5 Global Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
Table 6 Global Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
Table 7 Global Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
Table 8 Global Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
Table 9 Global Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
Table 10 Global Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 11 Global Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
Table 12 Global Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
Table 13 Global Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
Table 14 Global Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
Table 15 Global Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
Table 16 Global Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
Table 17 Global Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
Table 18 Global Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 19 Global Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 20 Global Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 21 Global Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 22 North America Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
Table 23 North America Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 24 North America Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
Table 25 North America Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
Table 26 North America Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
Table 27 North America Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
Table 28 North America Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
Table 29 North America Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
Table 30 North America Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
Table 31 North America Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 32 North America Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
Table 33 North America Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
Table 34 North America Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
Table 35 North America Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
Table 36 North America Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
Table 37 North America Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
Table 38 North America Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
Table 39 North America Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 40 North America Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 41 North America Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 42 North America Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 43 Europe Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
Table 44 Europe Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 45 Europe Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
Table 46 Europe Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
Table 47 Europe Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
Table 48 Europe Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
Table 49 Europe Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
Table 50 Europe Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
Table 51 Europe Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
Table 52 Europe Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 53 Europe Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
Table 54 Europe Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
Table 55 Europe Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
Table 56 Europe Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
Table 57 Europe Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
Table 58 Europe Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
Table 59 Europe Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
Table 60 Europe Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 61 Europe Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 62 Europe Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 63 Europe Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 64 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
Table 65 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 66 Asia Pacific Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
Table 67 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
Table 68 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
Table 69 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
Table 70 Asia Pacific Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
Table 71 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
Table 72 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
Table 73 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 74 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
Table 75 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
Table 76 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
Table 77 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
Table 78 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
Table 79 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
Table 80 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
Table 81 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 82 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 83 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 84 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 85 South America Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
Table 86 South America Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 87 South America Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
Table 88 South America Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
Table 89 South America Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
Table 90 South America Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
Table 91 South America Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
Table 92 South America Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
Table 93 South America Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
Table 94 South America Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 95 South America Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
Table 96 South America Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
Table 97 South America Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
Table 98 South America Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
Table 99 South America Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
Table 100 South America Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
Table 101 South America Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
Table 102 South America Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 103 South America Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 104 South America Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 105 South America Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 106 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
Table 107 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 108 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
Table 109 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
Table 110 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
Table 111 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
Table 112 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
Table 113 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
Table 114 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
Table 115 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 116 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
Table 117 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
Table 118 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
Table 119 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
Table 120 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
Table 121 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
Table 122 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
Table 123 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 124 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 125 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 126 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)

Product Code: SMRC30609

According to Stratistics MRC, the Global Liver Fibrosis Treatment Market is accounted for $20.71 billion in 2025 and is expected to reach $48.87 billion by 2032 growing at a CAGR of 13.05% during the forecast period. Treatment for liver fibrosis targets the reduction or reversal of scar tissue formation resulting from ongoing liver damage or inflammation. It involves managing the root cause like viral hepatitis, alcohol consumption, or nonalcoholic fatty liver alongside medications, lifestyle modifications, and supportive care to minimize further harm. Timely treatment helps preserve liver function, slows disease progression, and lowers the risk of developing cirrhosis, ultimately improving overall health and prognosis.

According to the National Institute on Alcohol Abuse and Alcoholism 2023, in 2022, about 29.5 million individuals in the United States with alcohol dependence, or 10.5% of individuals aged between 12 years and above.

Market Dynamics:

Driver:

Growing geriatric population

The increasing number of elderly individuals worldwide is significantly boosting demand for liver fibrosis treatments. Older adults are more prone to liver disorders due to age-related immune decline and long-term exposure to metabolic stressors. Conditions like obesity, diabetes, and heart disease often coexist, accelerating liver deterioration. As longevity rises, healthcare providers are seeing a growing need for therapies tailored to older patients. This trend is encouraging pharmaceutical innovation focused on safer and more effective anti-fibrotic options for seniors. Eventually, the aging demographic is expanding the treatment market and influencing the direction of clinical development.

Restraint:

Limited availability of approved anti-fibrotic drugs

Most available therapies concentrate on managing underlying causes such as viral hepatitis or fatty liver disease, rather than reversing fibrotic damage. Regulatory complexities and extended development timelines have slowed the introduction of new treatments. Many promising compounds are still in early research phases, leaving clinicians with few targeted solutions. This shortage affects patient care and restricts market expansion, particularly in high-burden regions. Until more anti-fibrotic agents receive approval, treatment options will remain constrained.

Opportunity:

Expansion of telemedicine and digital health platforms

The rise of digital health and telemedicine is opening new avenues for managing liver fibrosis. Virtual consultations allow patients to access liver specialists and receive timely care, especially in remote or underserved areas. Wearables and mobile apps can monitor liver function indicators and support medication adherence. These technologies also enable customized treatment plans and improve patient education, fostering better health outcomes. As digital healthcare becomes mainstream, liver fibrosis care is becoming more proactive and accessible. This shift is expected to drive broader adoption of innovative therapies and enhance disease management.

Threat:

Competition from alternative therapies

Alternative therapies are increasingly challenging the dominance of traditional liver fibrosis treatments. Preventive strategies like lifestyle changes, dietary interventions, and metabolic control are gaining traction as first-line approaches. Regenerative techniques and cell-based therapies also offer novel solutions that may bypass conventional drug treatments. This expanding range of options could reduce reliance on pharmacological interventions. Additionally, clinicians may be cautious about adopting new drugs if non-invasive methods prove effective.

Covid-19 Impact:

The COVID-19 pandemic had a notable effect on the Liver Fibrosis Treatment Market, causing delays in diagnostics, routine check-ups, and non-essential medical procedures. Treatment schedules were often postponed, resulting in possible disease advancement for some patients. Disruptions in supply chains hindered the availability of medicines and diagnostic tools. On the positive side, the crisis spurred the adoption of telemedicine and heightened awareness of liver health, as COVID-19's potential impact on liver function emphasized the importance of early detection and effective care.

The peroxisome proliferator segment is expected to be the largest during the forecast period

The peroxisome proliferator segment is expected to account for the largest market share during the forecast period, driven by advancements in drug discovery technologies, including high-throughput screening and molecular modelling. Emerging trends such as the development of dual and pan-PPAR agonists offer broader therapeutic benefits. Key developments include promising clinical trial results and strategic collaborations between pharmaceutical companies to accelerate innovation. Increasing prevalence of nonalcoholic steatohepatitis (NASH) and related metabolic disorders further fuels demand, positioning PPAR-based treatments as a vital segment in liver fibrosis management.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospital pharmacies segment is predicted to witness the highest growth rate, driven by advancements in pharmaceutical dispensing technologies, such as automated drug distribution and electronic prescription systems, enhancing efficiency and accuracy. Emerging trends include integration of telepharmacy services and personalized medicine approaches for liver disease patients. Developments like hospital collaborations with pharmaceutical companies for clinical trials and early drug access programs. Rising hospitalization rates for liver-related conditions and increasing availability of advanced therapies further strengthen the role of hospital pharmacies in treatment delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to escalating cases linked to hepatitis, NASH, and alcohol-induced liver damage. Innovations in non-invasive imaging and RNA therapeutics are enhancing early diagnosis and targeted care. The market is seeing growth in digital health adoption and personalized treatment approaches. Notable progress includes new drug candidates and expanded trial activity in India, Japan, and China. Aging populations, rising health awareness, and increased government investment are fueling technological advancement and regional market growth.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, due to growing prevalence of NASH, NAFLD, and hepatitis, supported by robust healthcare systems and research funding. Breakthroughs in AI-driven diagnostics, non-invasive technologies, and RNA therapeutics are improving accuracy and early intervention. Trends like telemedicine and tailored treatment approaches are gaining traction. Recent progress includes new PPAR-targeting drugs, multi-modal regimens, and expanded trial networks. Rising health literacy, favourable regulations, and active pharmaceutical pipelines are driving sustained market expansion across the region.

Key players in the market

Some of the key players in Liver Fibrosis Treatment Market include Abbott Laboratories, Bristol-Myers Squibb Company, Akero Therapeutics, Hepion Pharmaceuticals, Alentis Therapeutics, Inventiva Pharma, Alnylam Pharmaceuticals, Johnson & Johnson, Astellas Pharma Inc., Novartis AG, Boehringer Ingelheim, Merck & Co., Inc., Pfizer Inc., Sanofi AG, Vertex Pharmaceuticals Incorporated, Galectin Therapeutics, Inc., Takeda Pharmaceutical Company, Gilead Sciences, Inc., Madrigal Pharmaceuticals, Inc., and GlaxoSmithKline PLC.

Key Developments:

In July 2025, Johnson & Johnson MedTech announced a strategic co-promotion agreement with Pacira BioSciences, Inc., the industry leader in the delivery of innovative, non-opioid pain therapies. The agreement expands the Company's Early Intervention portfolio with ZILRETTA(R) (triamcinolone acetonide extended-release injectable suspension) an extended-release injectable for treatment of pain related to osteoarthritis (OA) of the knee.

In June 2025, Bristol Myers Squibb and BioNTech SE announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.

In February 2025, Abbott and Shedd Aquarium are announcing one of Shedd's largest corporate gifts in recent history - a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.

Treatment Types Covered:

ACE Inhibitors
Antiviral Drugs
Cell Therapy
Peroxisome Proliferator
FXR Agonists
Targeted Therapy
Hepatotropic Drugs
Other Treatment Types

Conditions Covered:

Nonalcoholic Steatohepatitis (NASH)
Chronic Liver Diseases
Hepatitis C
Alcoholic Liver Disease
Genetic Disorders
Autoimmune Hepatitis

Distribution Channels Covered:

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Liver Fibrosis Treatment Market, By Treatment Type

5.1 Introduction
5.2 ACE Inhibitors
5.3 Antiviral Drugs
5.4 Cell Therapy
5.5 Peroxisome Proliferator
5.6 FXR Agonists
5.7 Targeted Therapy
5.8 Hepatotropic Drugs
5.9 Other Treatment Types

6 Global Liver Fibrosis Treatment Market, By Condition

6.1 Introduction
6.2 Nonalcoholic Steatohepatitis (NASH)
6.3 Chronic Liver Diseases
6.4 Hepatitis C
6.5 Alcoholic Liver Disease
6.6 Genetic Disorders
6.7 Autoimmune Hepatitis

7 Global Liver Fibrosis Treatment Market, By Distribution Channel

7.1 Introduction
7.2 Hospital Pharmacies
7.3 Online Pharmacies
7.4 Retail Pharmacies

8 Global Liver Fibrosis Treatment Market, By Geography

8.1 Introduction
8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling

10.1 Abbott Laboratories
10.2 Bristol-Myers Squibb Company
10.3 Akero Therapeutics
10.4 Hepion Pharmaceuticals
10.5 Alentis Therapeutics
10.6 Inventiva Pharma
10.7 Alnylam Pharmaceuticals
10.8 Johnson & Johnson
10.9 Astellas Pharma Inc.
10.10 Novartis AG
10.11 Boehringer Ingelheim
10.12 Merck & Co., Inc.
10.13 Pfizer Inc.
10.14 Sanofi AG
10.15 Vertex Pharmaceuticals Incorporated
10.16 Galectin Therapeutics, Inc.
10.17 Takeda Pharmaceutical Company
10.18 Gilead Sciences, Inc.
10.19 Madrigal Pharmaceuticals, Inc.
10.20 GlaxoSmithKline PLC

肝線維症治療市場の2032年までの予測：治療タイプ、病態、流通チャネル、地域別の世界分析

Liver Fibrosis Treatment Market Forecasts to 2032 - Global Analysis By Treatment Type, Condition, Distribution Channel and By Geography

COVID-19の影響：

最大のシェアを占める地域：

CAGRが最も高い地域：

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の肝線維症治療市場：治療タイプ別

第6章 世界の肝線維症治療市場：病態別

第7章 世界の肝線維症治療市場：流通チャネル別

第8章 世界の肝線維症治療市場：地域別

第9章 主な発展

第10章 企業プロファイリング